


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177)**

**VOLUNTARY ANNOUNCEMENT**  
**CATEGORY I ANTI-TUMOR INNOVATIVE DRUG “TQB2930” OBTAINED**  
**APPROVAL FOR CLINICAL TRIAL**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that “TQB2930”, a Category I anti-tumor innovative drug for injection that is self-developed by the Group, has been approved by the National Medical Products Administration of the PRC to commence clinical trials for the treatment of patients with advanced malignant tumors.

TQB2930, being a bispecific antibody that targets solid tumor cells, crates enhanced synergistic effects on two targets. It can block genetic signals that drive tumor growth and kill tumor cells through multiple mechanisms. Preclinical efficacy studies have shown that this molecule can significantly inhibit tumor growth.

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 20 April 2022

*As at the date of this announcement, the Board of the Company comprises nine executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*